Literature DB >> 10457311

Cystic glucagonoma: A rare variant of an uncommon neuroendocrine pancreas tumor.

K Brown1, T Kristopaitis, S Yong, G Chejfec, J Pickleman.   

Abstract

Glucagon-producing neuroendocrine tumors typically present with a characteristic constellation of symptoms including necrolytic migratory erythema, non-insulin-dependent diabetes, weight loss, anemia, glossitis, and an increased thrombotic tendency. Most glucagonomas are solid and arise in the body or tail of the pancreas. We report two cases of cystic glucagonoma, one found incidentally in an asymptomatic patient and one in a patient with weight loss and diabetes but no rash. In the first patient, distal pancreatectomy and splenectomy were curative, whereas the second patient continued to exhibit elevated serum glucagon levels and symptoms of glucose intolerance in the absence of demonstrable metastases. Cystic glucagonoma is a unique variant of classic glucagonoma and should be considered in the differential diagnosis of cystic pancreatic neoplasms.

Entities:  

Mesh:

Year:  1998        PMID: 10457311     DOI: 10.1016/s1091-255x(98)80053-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.267


  29 in total

1.  The glucagonoma syndrome: surgically curable diabetes.

Authors:  G A Higgins; L Recant; A B Fischman
Journal:  Am J Surg       Date:  1979-01       Impact factor: 2.565

2.  Glucagonoma syndrome in a 19-year-old woman.

Authors:  M C Riddle; T A Golper; W S Fletcher; J W Ensinck; P H Smith
Journal:  West J Med       Date:  1978-07

3.  Cystic glucagonoma with loss of heterozygosity on chromosome 11 in multiple endocrine neoplasia type 1.

Authors:  H Sarui; K Yoshimoto; S Okumura; M Kamura; H Takuno; T Ishizuka; H Takao; K Shimokawa; M Itakura; S Saji; K Yasuda
Journal:  Clin Endocrinol (Oxf)       Date:  1997-04       Impact factor: 3.478

4.  Necrolytic migratory erythema with carcinoma of the pancreas.

Authors:  D S Wilkinson
Journal:  Trans St Johns Hosp Dermatol Soc       Date:  1973

5.  Cystic tumors of the pancreas. New clinical, radiologic, and pathologic observations in 67 patients.

Authors:  A L Warshaw; C C Compton; K Lewandrowski; G Cardenosa; P R Mueller
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

Review 6.  Glucagonomas and insulinomas.

Authors:  G Boden
Journal:  Gastroenterol Clin North Am       Date:  1989-12       Impact factor: 3.806

7.  The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours.

Authors:  B Eriksson; E T Janson; N D Bax; M Mignon; R Morant; P Opolon; P Rougier; K E Oberg
Journal:  Digestion       Date:  1996       Impact factor: 3.216

8.  Glucagonoma occurring as a large cystic abdominal mass.

Authors:  P W Ho; G W Moore; A F Hoge
Journal:  South Med J       Date:  1984-05       Impact factor: 0.954

Review 9.  Gastrointestinal neuroendocrine tumors.

Authors:  R Delcore; S R Friesen
Journal:  J Am Coll Surg       Date:  1994-02       Impact factor: 6.113

10.  Operative and chemotherapeutic management of malignant glucagon-producing tumors.

Authors:  R A Prinz; K Badrinath; M Banerji; M Sparagana; T R Dorsch; A M Lawrence
Journal:  Surgery       Date:  1981-10       Impact factor: 3.982

View more
  4 in total

Review 1.  Deciphering the cells of origin of squamous cell carcinomas.

Authors:  Adriana Sánchez-Danés; Cédric Blanpain
Journal:  Nat Rev Cancer       Date:  2018-09       Impact factor: 60.716

2.  Cystic pancreatic neuroendocrine tumors: is preoperative diagnosis possible?

Authors:  Steven A Ahrendt; Richard A Komorowski; Michael J Demeure; Stuart D Wilson; Henry A Pitt
Journal:  J Gastrointest Surg       Date:  2002 Jan-Feb       Impact factor: 3.452

Review 3.  Pathologic pancreatic endocrine cell hyperplasia.

Authors:  Debra Ouyang; Deepti Dhall; Run Yu
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

4.  Radio-guided surgery with the use of [99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract.

Authors:  A Hubalewska-Dydejczyk; J Kulig; P Szybinski; R Mikolajczak; D Pach; A Sowa-Staszczak; K Fröss-Baron; B Huszno
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-07-25       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.